Adakveo

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

GlioblastomaSickle Cell DiseaseAnemia

160 competitors in Glioblastoma

#DrugCompanyPhaseTrials

1

Avastin

Roche

Phase 3

582

Keytruda

Merck & Co.

Phase 3

243

Opdivo

Bristol-Myers Squibb

Phase 3

184

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1605

Yervoy

Bristol-Myers Squibb

Phase 3

116

Ceenu

AAzurity Pharmaceuticals

Phase 3

217

Antabuse

Teva

Phase 3

58

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

49

Feraheme

AAzurity Pharmaceuticals

Phase 3

410

Adakveo

Novartis

Approved

1Show 45 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Sickle Cell Disease7 trials

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Completed·Novartis·Phase 2·NCT03264989·57 enrolled

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

Completed·Novartis·Phase 2·NCT03474965·117 enrolled

A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

Completed·Novartis·Phase 2·NCT03938454·36 enrolled

Show 4 more trials

An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients

Completed·Novartis·Phase 4·NCT04662931·140 enrolled

MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients

Available·Novartis··NCT03720626

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Recruiting·Novartis·Phase 4·NCT04657822·130 enrolled

A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) Versus Placebo, With or Without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Frequent Vaso-Occlusive Crises

Recruiting·Novartis·Phase 3·NCT06439082·354 enrolled

COVID-192 trials

Crizanlizumab for Treating COVID-19 Vasculopathy

Completed·JJohns Hopkins University·Phase 2·NCT04435184·54 enrolled

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Completed·MMatthew Neal MD·Phase 4·NCT04505774·3,591 enrolled

Anemia1 trial

Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia

Not yet recruiting·—·Phase 1/2·NCT05469828·30 enrolled

Glioblastoma1 trial

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

Recruiting·SSheba Medical Center·Phase 2·NCT05909618·33 enrolled

Myelofibrosis1 trial

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Terminated·Novartis·Phase 1/2·NCT04097821·45 enrolled

2 more indications

Encephalopathy1 trial

Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT04611880·20 enrolled

Sickle Cell Disease (SCD)1 trial

A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)

Active, not recruiting·Novartis·Phase 3·NCT03814746·254 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News